About Haley Chartres

This author has yet to write their bio.
Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 157 entries.

Entries by Haley Chartres

Botanix co-founder says interest for sweat-stopper gel is keeping him bullish ahead of FDA review | The West Australian

February 14, 2023 in , , /by

Botanix’s co-founder and Executive Director, Matt Callahan, was featured in a story in The West Australian newspaper by business reporter Cheyanne Encisco. The article highlighted the FDA’s upcoming mid-cycle review of Botanix’s application for its lead product, Sofpironium Bromide gel, for the treatment of primary axillary hyperhidrosis, also known as excessive underarm sweating. In the […]

This broker says Botanix Pharma’s share price could more than triple on an FDA approval | Stockhead

February 14, 2023 in , , /by

A recent analyst report by Euroz Hartleys predicting significant upside for Botanix if the Company’s Sofpironium Bromide New Drug Application (NDA) is successful, has been featured on Stockhead. Journalist Eddy Sunarto highlighted the analyst’s prediction that the share price could triple if FDA approval for the treatment of primary axillary hyperhidrosis is achieved in Q3 of […]

Analyst Report by Euroz Hartleys – 01 February 2023

February 1, 2023 in , , /by

Euroz Hartleys has published an analyst note, reporting that the mid-cycle review for Botanix’s FDA New Drug Application (NDA) for Sofpironium Bromide remains on track for this quarter (Q1 CY23). Analyst Seth Lizée noted the experience of the Botanix team in securing FDA-approval, and successfully commercialising over 30 products. He classified Botanix as a ‘Speculative Buy, Target Price […]

BOT Video | Not To Be Missed

January 30, 2023 in , /by

Botanix has united three experts to explain why its lead product, Sofpironium Bromide, is on track to define the success of Botanix this quarter. Hear from one of the world’s most highly experienced dermatology specialists, former head of the American Academy of Dermatology and Founding President of the International Hyperhidrosis Society, Prof. David Pariser; together […]

JP Morgan Healthcare Conference Presentation

January 8, 2023 in , , /by

Botanix will be attending the JP Morgan Healthcare Conference in San Francisco this week. The conference attracts more than 50,000 attendees from around the world, bringing together global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community. As part of the conference, Botanix will be discussing the significant commercial potential […]

Research Report by Euroz Hartleys – 8 December 2022

December 8, 2022 in , , /by

Botanix is pleased to share an analyst report published by Euroz Hartleys following this week’s announcement that our Company has received formal written communication from the FDA, confirming that our New Drug Application (NDA) for Sofpironium Bromide is suitable for substantive review, and that no issues have been identified. Analyst Seth Lizee classified the Company […]

SPP Now Open

November 8, 2022 in , , , /by

Botanix’s recently announced Share Purchase Plan (SPP) to raise up to A$3 million is now open for eligible AU/NZ shareholders. The SPP opens today, 9 November 2022 and will remain open until 8:00pm AEDT on Wednesday, 23 November 2022 (unless extended or withdrawn).  As the SPP is only open for two weeks, eligible shareholders are […]